What does this score mean?
The Confidence Index is an editorial methodology score that indicates the extent to which the scientific findings evaluated on this page can be relied upon, not the success rate of the treatment. Study design, risk of bias, sample size, precision, direct applicability, reproducibility, transparency, and clinical relevance are evaluated together.
What did the study investigate?
It evaluated whether online peptide dosing charts can be used as clinical prescriptions or standard therapeutic doses.
How was it done?
Research protocols for different peptides, early-phase human data, animal studies, and secondary sources on biohacking platforms were compared.
What was found?
It was found that sources varied widely in terms of level of evidence, product standardization, indication, and pharmacokinetics; research doses cannot be directly translated into clinical prescriptions.
Limitations of the study
This page is based on a methodological evaluation of heterogeneous secondary sources, not a single primary clinical study. The level of evidence varies significantly across molecules.
What does this mean clinically?
Peptides can only be evaluated by examining regulatory status, phase of human data, indication, and safety together on a molecule-by-molecule basis; online dosing charts alone are not clinical decision-making tools.
What do we not know yet?
For many research peptides, reliable long-term human data, standardized product quality, and established dosage ranges are not yet available.
Source
The full citations and links of the sources are preserved in the detailed evaluation section of this page.
Written and medically reviewed by: Dr. Kerem Çağlayan · Information about peptide applications · All Scientific Research
Detailed evaluation
Source and evidence evaluation · September 18, 2026
The peptide ecosystem is growing rapidly. On performance/biohacking platforms such as NinjAthlete, “research dose” tables are published for molecules such as BPC-157, TB-500, GHK-Cu, KPV, retatrutide, tesamorelin, AOD-9604, CJC-1295/ipamorelin, and MOTS-c.
Key distinction: research dose ≠ clinical prescription
Such charts can compile data from animal studies, early-phase human trials, clinical research protocols, and community practices. However, the level of evidence from these sources is not the same. Just because a dose was used in an experimental study does not mean it is an effective and safe clinical dose for a specific disease.
NinjAthlete’s dose calculator also states that its outputs are for educational and research purposes and do not substitute for medical advice or a prescription.
Why can it not be directly translated into a prescription?
- Difference in evidence by molecule: The level of human randomized data varies from molecule to molecule.
- Difference in indication: An experimental dose in one indication cannot be generalized to another purpose.
- Formulation and purity: A research product and an approved pharmaceutical product may not have the same quality assurance.
- Pharmacokinetics: Bioavailability differs across routes of administration.
- Long-term safety: For many molecules, long-term human data is limited.
Clinical approach
When evaluating peptides, regulatory status, phase of human data, studied indication, primary endpoints, and safety signals must be examined separately. For this reason, such tables will not be presented as a clinical prescription standard on our site.
Quality of evidence
Secondary/review source evaluation.
References
This content does not recommend the use or dosage of any research peptide.
